Medico Intercontinental Limited Stock

Equities

539938

INE858Q01019

Pharmaceuticals

Market Closed - Bombay S.E. 03:00:41 2024-05-18 EDT 5-day change 1st Jan Change
47.8 INR 0.00% Intraday chart for Medico Intercontinental Limited +8.27% -48.57%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site

Financials

Sales 2022 743M 8.93M 12.15M Sales 2023 765M 9.19M 12.51M Capitalization 829M 9.96M 13.56M
Net income 2022 31M 372K 507K Net income 2023 36M 432K 589K EV / Sales 2022 0.35 x
Net Debt 2022 68.71M 825K 1.12M Net cash position 2023 20.66M 248K 338K EV / Sales 2023 1.06 x
P/E ratio 2022
6.1 x
P/E ratio 2023
14.8 x
Employees 25
Yield 2022 *
-
Yield 2023
0.12%
Free-Float 31.04%
More Fundamentals * Assessed data
Dynamic Chart
Medico Intercontinental Limited Announces Resignation of Nikul Dipakbhai Shah as Independent Director CI
Medico Intercontinental Limited Proposes to Incorporate Joint Venture Partnership Firm CI
Medico Intercontinental Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Medico Intercontinental Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Medico Intercontinental Limited Approves Final Equity Dividend for the Financial Year 2022-23 CI
Medico Intercontinental Limited Approves the Regularisation of Priyank Lalitbhai Sancheti as an Independent Director CI
Medico Intercontinental Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Medico Intercontinental Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Medico Intercontinental Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023, Payable on or After July 5, 2023 CI
Medico Intercontinental Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Medico Intercontinental Limited Appoints Priyank L Sancheti as an Additional Independent Director CI
Medico Intercontinental Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Medico Intercontinental Limited Approves Regularisation of Nikul Dipakbhai Shah as an Independent Director CI
Medico Intercontinental Limited announced that it expects to receive INR 249.787 million in funding CI
Medico Intercontinental Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
More news
1 week+8.27%
Current month+8.51%
1 month+8.39%
3 months-36.73%
6 months-44.41%
Current year-48.57%
More quotes
1 week
44.00
Extreme 44
50.28
1 month
41.52
Extreme 41.52
50.28
Current year
39.00
Extreme 39
122.00
1 year
39.00
Extreme 39
122.00
3 years
24.80
Extreme 24.8
122.00
5 years
14.70
Extreme 14.7
122.00
10 years
8.00
Extreme 8
132.10
More quotes
Managers TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 19-08-11
Compliance Officer - 19-05-31
Members of the board TitleAgeSince
Corporate Officer/Principal 46 18-08-13
Chairman - 18-08-13
Director/Board Member 51 19-03-22
More insiders
Date Price Change Volume
24-05-18 47.8 -0.19% 3,110
24-05-17 47.89 +5.00% 10,094
24-05-16 45.61 -4.70% 7,457
24-05-15 47.86 +0.97% 3,004
24-05-14 47.4 +4.24% 811

Delayed Quote Bombay S.E., May 18, 2024 at 03:00 am

More quotes
Medico Intercontinental Ltd is engaged in the business of trading of pharmaceutical products. It provides platform to all research-based biopharmaceutical companies. Its product categories include gastro, uro, nutrition, cosmetology, health devices, hospital, and other areas. Its products include ACIFACT-BLI, ACIFACT-P, ACIFACT-SP (ALU-ALU), ALBECTIN, ALFACARE - D3, ARSUFACT Combokit, BALOFACT, CYCLOFACT 400, UDIFACT 150, XOFACT - 4, ZIFT SL - 250, ZYMIX, ARGIFACT, CLIANCIACT POWDER, RELIEVE CZ, VOLIREX SPRAY, RACIMAX SACHET, PERMACT, OROFACT, KTZ, FEMYACT, LIVOFACT, ZYMIX SY, ULTRATONE SY, ALBECTIN SUS, BECOFACT DROPS, MEFACT P SUS, ONCARE SOLUTION, OFCARE-FORTE SUS, PRODOM CV SY., RELIBEN SUSP., ZIFT SUSP.-200 MGCIPACT EYE DROP, OROFACT-PASTE(lamy), OROFACT MOUTH ULCER GEL, CALAMED LOTION and others. Its subsidiaries include Evagrace Pharma Private Limited, Ritz Formulations Private Limited, Sungrace Pharma Private Limited, and Azillian Healthcare Private Limited.
More about the company
  1. Stock Market
  2. Equities
  3. 539938 Stock
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW